Silver Book Fact

Economic value from flu vaccine in elderly

As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest economic benefit.

Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, et al. The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs. Vaccine. 2007; 25: 5086-96. http://download.thelancet.com/flatcontentassets/H1N1-flu/epidemiology/epidemiology-14.pdf

Reference

Title
The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs
Publication
Vaccine
Publication Date
2007
Authors
Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, et al.
Pages
5086-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Cost savings from immunization
    Every dollar spent on immunization saves $6.30 in direct medical costs – a total savings of $10.5 billion. When including indirect costs such as lost days of work, disability,…  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.  
  • Economic value from flu vaccine in elderly
    As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest…  
  • Staff flu vaccination reduces incidence of staff and patients
    Vaccination of staff in a tertiary care facility over a period of 12 influenza seasons increased vaccination coverage from 4% to 67%, reduced laboratory-confirmed cases of influenza amongst staff from…  
  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.